NCT01579253

Brief Summary

Patients with recurrent glioblastoma who are planned to receive a second course of radiation are to be included into this monocentric cohort trial. Due to multiple pre-treatments simultaneous combined positron emission tomography (PET) with O-(2-\[18F\]fluoroethyl)-l-tyrosine (FET) as well as magnetic resonance imaging (MRI) is used for treatment planning and follow-up imaging as it allows for a better distinction between treatment-related changes and viable tumor tissue.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

April 15, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 17, 2012

Completed
Last Updated

December 18, 2012

Status Verified

December 1, 2012

First QC Date

April 15, 2012

Last Update Submit

December 17, 2012

Conditions

GlioblastomaNervous System NeoplasmsCentral Nervous System NeoplasmsAstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms by Histologic TypeNeoplasms, Nerve Tissue

Keywords

Recurrent glioblastomaRadiotherapyPET-MRIFET-PET

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with recurrent glioblastoma who are planned to receive a re-irradiation

You may qualify if:

  • years old
  • histologically or magnetic resonance imaging proven recurrent glioblastoma
  • re-irradiation possible
  • willing and able to give free informed consent

You may not qualify if:

  • not willing or able to give free informed consent
  • pregnancy
  • claustrophobia
  • metallic objects or implanted medical devices in the body

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Munich, Dep. of Radiation Oncology

Munich, Bavaria, 81377, Germany

RECRUITING

MeSH Terms

Conditions

GlioblastomaNervous System NeoplasmsCentral Nervous System NeoplasmsAstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms by Histologic TypeNeoplasms, Nerve Tissue

Condition Hierarchy (Ancestors)

Neoplasms, Germ Cell and EmbryonalNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms by SiteNervous System Diseases

Study Officials

  • Maximilian Niyazi, MD, MSc

    Ludwig-Maximilians - University of Munich

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maximilian Niyazi, MD, MSc

CONTACT

00498970953770Maximilian.Niyazi@med.uni-muenchen.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 15, 2012

First Posted

April 17, 2012

Study Start

April 1, 2012

Last Updated

December 18, 2012

Record last verified: 2012-12

Locations

DE(1)